Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Tania Jain, Merav Bar, Ankit J. Kansagra, Elise A. Chong, Shahrukh K. Hashmi, Sattva S. Neelapu, Michael Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron A. Jacobson, Stephen M. Ansell, Farrukh T. Awan, Linda Burns, Veronika Bachanova, Catherine M. Bollard, Paul A. Carpenter, John F. DiPersio, Mehdi Hamadani, Helen E. Heslop, Joshua A. HillKrishna V. Komanduri, Craig A. Kovitz, Hillard M. Lazarus, Justin M. Serrette, Mohamad Mohty, David Miklos, Arnon Nagler, Steven Z. Pavletic, Bipin N. Savani, Stephen J. Schuster, Mohamed A. Kharfan-Dabaja, Miguel Angel Perales, Yi Lin

Research output: Contribution to journalReview article

Abstract

Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Antigen Receptors
Expert Testimony
B-Cell Lymphoma
Cell- and Tissue-Based Therapy
Non-Hodgkin's Lymphoma
Transplantation
CD19 Antigens
Lymphoma
T-Cell Antigen Receptor
Immunotherapy
T-Lymphocytes
Therapeutics
Los Angeles
Cell Transplantation
Health
Hematology
United States Food and Drug Administration
Switzerland
Canada
Patient Care

Keywords

  • Chimeric antigen receptor T cell therapy
  • Diffuse large B cell lymphoma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma : An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. / Jain, Tania; Bar, Merav; Kansagra, Ankit J.; Chong, Elise A.; Hashmi, Shahrukh K.; Neelapu, Sattva S.; Byrne, Michael; Jacoby, Elad; Lazaryan, Aleksandr; Jacobson, Caron A.; Ansell, Stephen M.; Awan, Farrukh T.; Burns, Linda; Bachanova, Veronika; Bollard, Catherine M.; Carpenter, Paul A.; DiPersio, John F.; Hamadani, Mehdi; Heslop, Helen E.; Hill, Joshua A.; Komanduri, Krishna V.; Kovitz, Craig A.; Lazarus, Hillard M.; Serrette, Justin M.; Mohty, Mohamad; Miklos, David; Nagler, Arnon; Pavletic, Steven Z.; Savani, Bipin N.; Schuster, Stephen J.; Kharfan-Dabaja, Mohamed A.; Perales, Miguel Angel; Lin, Yi.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalReview article

Jain, T, Bar, M, Kansagra, AJ, Chong, EA, Hashmi, SK, Neelapu, SS, Byrne, M, Jacoby, E, Lazaryan, A, Jacobson, CA, Ansell, SM, Awan, FT, Burns, L, Bachanova, V, Bollard, CM, Carpenter, PA, DiPersio, JF, Hamadani, M, Heslop, HE, Hill, JA, Komanduri, KV, Kovitz, CA, Lazarus, HM, Serrette, JM, Mohty, M, Miklos, D, Nagler, A, Pavletic, SZ, Savani, BN, Schuster, SJ, Kharfan-Dabaja, MA, Perales, MA & Lin, Y 2019, 'Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.08.015
Jain, Tania ; Bar, Merav ; Kansagra, Ankit J. ; Chong, Elise A. ; Hashmi, Shahrukh K. ; Neelapu, Sattva S. ; Byrne, Michael ; Jacoby, Elad ; Lazaryan, Aleksandr ; Jacobson, Caron A. ; Ansell, Stephen M. ; Awan, Farrukh T. ; Burns, Linda ; Bachanova, Veronika ; Bollard, Catherine M. ; Carpenter, Paul A. ; DiPersio, John F. ; Hamadani, Mehdi ; Heslop, Helen E. ; Hill, Joshua A. ; Komanduri, Krishna V. ; Kovitz, Craig A. ; Lazarus, Hillard M. ; Serrette, Justin M. ; Mohty, Mohamad ; Miklos, David ; Nagler, Arnon ; Pavletic, Steven Z. ; Savani, Bipin N. ; Schuster, Stephen J. ; Kharfan-Dabaja, Mohamed A. ; Perales, Miguel Angel ; Lin, Yi. / Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma : An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. In: Biology of Blood and Marrow Transplantation. 2019.
@article{4f2495d82e6349bfa011942c2f9e29ce,
title = "Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy",
abstract = "Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.",
keywords = "Chimeric antigen receptor T cell therapy, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma",
author = "Tania Jain and Merav Bar and Kansagra, {Ankit J.} and Chong, {Elise A.} and Hashmi, {Shahrukh K.} and Neelapu, {Sattva S.} and Michael Byrne and Elad Jacoby and Aleksandr Lazaryan and Jacobson, {Caron A.} and Ansell, {Stephen M.} and Awan, {Farrukh T.} and Linda Burns and Veronika Bachanova and Bollard, {Catherine M.} and Carpenter, {Paul A.} and DiPersio, {John F.} and Mehdi Hamadani and Heslop, {Helen E.} and Hill, {Joshua A.} and Komanduri, {Krishna V.} and Kovitz, {Craig A.} and Lazarus, {Hillard M.} and Serrette, {Justin M.} and Mohamad Mohty and David Miklos and Arnon Nagler and Pavletic, {Steven Z.} and Savani, {Bipin N.} and Schuster, {Stephen J.} and Kharfan-Dabaja, {Mohamed A.} and Perales, {Miguel Angel} and Yi Lin",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.08.015",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma

T2 - An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

AU - Jain, Tania

AU - Bar, Merav

AU - Kansagra, Ankit J.

AU - Chong, Elise A.

AU - Hashmi, Shahrukh K.

AU - Neelapu, Sattva S.

AU - Byrne, Michael

AU - Jacoby, Elad

AU - Lazaryan, Aleksandr

AU - Jacobson, Caron A.

AU - Ansell, Stephen M.

AU - Awan, Farrukh T.

AU - Burns, Linda

AU - Bachanova, Veronika

AU - Bollard, Catherine M.

AU - Carpenter, Paul A.

AU - DiPersio, John F.

AU - Hamadani, Mehdi

AU - Heslop, Helen E.

AU - Hill, Joshua A.

AU - Komanduri, Krishna V.

AU - Kovitz, Craig A.

AU - Lazarus, Hillard M.

AU - Serrette, Justin M.

AU - Mohty, Mohamad

AU - Miklos, David

AU - Nagler, Arnon

AU - Pavletic, Steven Z.

AU - Savani, Bipin N.

AU - Schuster, Stephen J.

AU - Kharfan-Dabaja, Mohamed A.

AU - Perales, Miguel Angel

AU - Lin, Yi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.

AB - Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.

KW - Chimeric antigen receptor T cell therapy

KW - Diffuse large B cell lymphoma

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85072519127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072519127&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.08.015

DO - 10.1016/j.bbmt.2019.08.015

M3 - Review article

C2 - 31446199

AN - SCOPUS:85072519127

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -